MDxHealth Announces Publication of Health Economic Analysis Demonstrating Cost-Savings of ConfirmMDx for Prostate Cancer

MDxHealth Announces Publication of Health Economic Analysis Demonstrating Cost-Savings of ConfirmMDx for Prostate Cancer 
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary
Repeated Prostate Biopsies and Reduce Healthcare Spending 
IRVINE, CA and LIEGE, BELGIUM -- (Marketwire) -- 02/14/13 -- 
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular
diagnostic company that develops and commercializes epigenetic tests
to support cancer diagnosis and treatment, today announced the
publication of results from a health economic study in the Journal of
American Health & Drug Benefits. The budget impact analysis
demonstrated achievable cost savings of MDxHealth's ConfirmMDx(TM)
for Prostate Cancer test, which is used by urologists to identify men
who may avoid unnecessary repeat prostate biopsies, thereby reducing
overall healthcare spending. 
The analysis projected the benefits, costs, and cost savings of the
ConfirmMDx for Prostate Cancer test based on empirical evidence of
its clinical effectiveness compared to a standard of care reference
scenario not using the assay. The goal was to quantify the impact on
costs by avoiding medically unnecessary repeat prostate biopsy
procedures for a managed care plan of one million members that
reimburses for the ConfirmMDx for Prostate Cancer test. A budget
impact model was built to test the hypothesis that the ConfirmMDx for
Prostate Cancer test can produce cost savings to payers as well as
benefits to urologists and patients by providing actionable guidance
to treat with more appropriate and less costly care.  
The analysis demonstrated that a commercial health plan would realize
cost savings within the first year of establishing coverage for the
ConfirmMDx for Prostate Cancer test. The upfront cost will be
recovered based on the savings associated with avoided biopsy
procedures and associated complications. Given these assumptions and
the costs associated with the current standard of care, the inclusion
of the test into the management of men screened for prostate cancer
resulted in a net cost savings of $588.00 per patient or budget
impact of -$0.5 million in a managed care plan of one million
"Even with conservative assumptions, our budget impact analysis
demonstrates that the ConfirmMDx 
for Prostate Cancer test can provide
economic returns that may generate net cost savings to health plans
by reducing unnecessary prostate biopsies, thus improving clinical
management and patient outcomes," said lead author Wade Aubry, M.D.,
Senior Medical Director for Quorum Consulting and Associate Clinical
Professor of Medicine at the University of California, San Francisco.
"ConfirmMDx demonstrates the exciting potential of personalized
medicine. In today's cost-conscious healthcare environment,
well-validated molecular tests hold the promise to address not only
unmet clinical needs, but also provide health economic benefits."  
About Prostate Cancer 
 Prostate cancer is the most frequent cancer
in men worldwide, with one out of six men being diagnosed with
prostate cancer in a lifetime. In the United States approximately 19
million men are screened with the PSA test on an annual basis,
leading to more than 1.3 million biopsy procedures and about 240,890
newly diagnosed cases.  
About ConfirmMDx for Prostate Cancer 
 Over 650,000 American men
receive a negative prostate biopsy result each year; though
approximately 25% of these men may still harbor occult prostate
cancer. This well-documented risk of undetected cancer, often with
clinically significant Gleason scores, leads to a high rate of repeat
biopsies with over 40% of men receiving at least one repeat biopsy,
and many receiving a 3rd and 4th biopsy. Today's gold standard
diagnostic approach is the prostate biopsy procedure, collecting
10-12 needle core biopsy samples, however, this sampling represents
less than 1% of the volume of a man's prostate gland. ConfirmMDx for
Prostate Cancer is an epigenetic assay to help urologists distinguish
patients who have a true-negative biopsy from those at risk for
occult cancer. The test is able to detect an epigenetic field effect
or "halo" associated with the cancerization process at the DNA level
in cells adjacent to cancer foci. This molecular "halo" around a
cancer lesion can be present despite having a normal appearance under
the microscope. The test helps urologists rule out prostate
cancer-free men from undergoing unnecessary repeat biopsies and,
helps rule in high risk patients who may require repeat biopsies and
potential treatment. 
About MDxHealth
 MDxHealth is a molecular diagnostics company that
develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The company's
first commercial product, the ConfirmMDx for Prostate Cancer test,
has been shown to help distinguish patients who have a true-negative
biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for brain and lung cancers. The company is
based in Irvine, California with a European headquarters in Liege,
Belgium. For more information visit MDxHealth website at 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. This
press release does not constitute an offer or invitation for the sale
or purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws. 
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
Dr Jan Groen
US: +1 949 812 6979 
BE: +32 4 364 20 70  
Mike Sinclair 
Halsin Partners 
UK: +44 20 7318 2955 
Cell: +44 7968 022075  
Seth Lewis 
The Trout Group 
US: +1 646 378 2952 
Press spacebar to pause and continue. Press esc to stop.